EU approves fifth copy of AbbVie's $18 billion drug Humira
Europe has approved a fifth copy of AbbVie's $18-billion-a-year biologic drug Humira – the world's best-selling prescription medicine – ramping up competition among makers of less-expensive biotech drugs.
from Reuters: Health News https://reut.rs/2pq04wa
http://bit.ly/2zwRqiM